Biotech Bullish Stocks: Idenix Pharmaceuticals Inc (NASDAQ:IDIX), Enzymotec Ltd (NASDAQ:ENZY), bluebird bio Inc (NASDAQ:BLUE), Athersys, Inc. (NASDAQ:ATHX)

xBoston hedge fund manager Baupost Group grew its portfolio of U.S. stocks by17 percent to $4.14 billion in the first quarter, maintaining large positions in several companies, including Cambridge-based Idenix Pharmaceuticals Inc (NASDAQ:IDIX). Idenix Pharmaceuticals Inc (NASDAQ:IDIX) stock performance was 6.06% in last session and finished the day at $6.03. Traded volume was 789,231 shares in the last session and the average volume of the stock remained 1.29 million shares. The beta of the stock remained -0.04. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) insider ownership is 25.11%.

Stock analysts at Jefferies Group dropped their price target on shares of Enzymotec Ltd (NASDAQ:ENZY) from $25.00 to $14.50 in a report issued on Monday. Jefferies Group’s target price would indicate a potential upside of 12.40% from the stock’s previous close. The analysts wrote, “Our $14.50 (down from $25) price target is based on a sector regression, SOTP and DCF models and implies Enzymotec trades at 12.6x 2015E EPS and 8.2x EBITDA.” Enzymotec Ltd (NASDAQ:ENZY) rose 8.53% to $14.00 yesterday on volume of 619,513 shares. The intra-day range of the stock was $12.50 – 14.10. Enzymotec Ltd (NASDAQ:ENZY) has a market capitalization of $301.91 million.

bluebird bio Inc (NASDAQ:BLUE)’s COO Jeffrey Walsh sold 1,500 shares of bluebird bio stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $20.03, for a total transaction of $30,045.00. bluebird bio Inc (NASDAQ:BLUE)’s stock on May 19, 2014 reported a increase 6.16% to the closing price of $26.73. Its fifty two weeks range is $17.03 – 36.25. The total market capitalization recorded $655.20 million. The overall volume in the last trading session was 513,082 shares. In its share capital, bluebird bio Inc (NASDAQ:BLUE) has 24.51 million outstanding shares.

Athersys, Inc. (NASDAQ:ATHX) first quarter 2014 net loss of 15 cents per share was wider than the Zacks Consensus Estimate of a loss of 9 cents. The company had suffered a loss of 18 cents per share in the year-ago quarter. Revenues increased to $0.7 million from $0.3 million recorded a year ago, driven by higher grant revenues. On Monday, shares of Athersys, Inc. (NASDAQ:ATHX) advanced 6.94% to close the day at $1.54. Company return on investment (ROI) is -122.50% and its monthly performance is recorded as -43.59%. Athersys, Inc. (NASDAQ:ATHX) quarterly revenue growth is -59.26%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone